The Accelerated Access Collaborative (AAC) is a unique partnership hosted by NICE bringing industry, government and the NHS together to remove barriers to uptake of innovations, so that NHS patients have faster access to innovations that can transform care.
See the 'Resources' section on the right to find out more about the AAC.
The innovations included in the AAC are:
- Urolift for lower urinary tract symptoms of benign prostatic hyperplasia – A cost-saving device that relieves painful urinary tract symptoms in men.
- HeartFlow Analysis for estimating fractional flow reserve from coronary CT angiography – A non-invasive personalised cardiac test that reduces the need for unnecessary procedures.
- Placental growth factor (PIG-F) based testing for suspected pre-eclampsia – Tests for early diagnosis of pre-eclampsia in pregnant women, which if unmonitored, can cause serious complications for mother and baby.
- PCSK9 inhibitors for treatment of primary hypercholesterolaemia and mixed dyslipidaemia – Cost effective drugs that significantly lower cholesterol and fats in the blood in patients at increased risk of heart disease and narrowed arteries.
- High sensitivity troponin tests for early rule out of myocardial infarction – Diagnostic tests that detect whether or not a patient is at risk or previously had a heart attack.
- Quantitative faecal immunochemical tests for colorectal cancer – Diagnostic tests that reduce referrals for patients with suspected colorectal cancer.
- Cladribine for treating highly active relapsing-remitting multiple sclerosis in adults – A drug for multiple sclerosis with a novel mode of action, high efficacy and a low treatment and monitoring burden.
2020/21 Pathway Transformation Fund (PTF)
**Please note the application period for the products below has now closed.**
Applications for phase 3 of the PTF opened on Monday 4 January 2021. The fund supports NHS organisations increase adoption of the 2020/21 Rapid Uptake Products RUPs
, which are:
- Lipid Management: High Intensity Statins, Ezetimibe and PCSK9 inhibitors
- Measuring fractional exhaled nitric oxide (FeNO) concentration in asthma: products NIOX VERO and NObreath
- Biologics for treating severe asthma: Reslizumab, Benralizumab, Mepolizumab and Omalizumab
The PTF can help providers overcome practical obstacles to introducing these products, such as:
- Support set-up costs such as training and accreditation of staff;
- Pathway redesign and/or business support expertise;
- Providing funding for specialist nurses and clinical staff needed to implement a new part of the procedure; and
- Covering double running costs
- Capital costs.
NHS organisations were invited to submit applications for PTF from 4 January 2021 until 12noon 30 April 2021.